We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024 Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX:...
New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024 Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award Allschwil...
Amended terms of Idorsia’s 2024 convertible bonds become effective Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced...
Idorsia announces financial results for the first half 2024 Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its...
Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST...
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension Idorsia receives approval from the European Commission (EC) for JERAYGO™...
Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds Allschwil, Switzerland – June 28, 2024 Idorsia Ltd...
Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2024 Idorsia...
Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category Idorsia’s dual orexin receptor antagonist, a...
Idorsia holds its Annual General Meeting of Shareholders All Board proposals approved by the shareholders Allschwil, Switzerland – June 13, 2024At today’s Annual General Meeting (AGM) of Idorsia...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions